Orforglipron (OFG) 45 mg achieved **12.13 kg** weight loss and **-1.65%** HbA1c reduction
Metabolic and Glycemic Effects of Orforglipron, a GLP-1 Receptor Agonist, in Adults With or Without Diabetes: A Network Meta-Analysis of Randomised Clinical Trials.
Background
Type 2 diabetes mellitus (T2DM) and obesity are prevalent metabolic disorders requiring effective long-term management. Current therapies, including injectable GLP-1 receptor agonists (GLP-1 RAs), offer benefits but often face adherence challenges due to administration route. Oral small-molecule GLP-1 RAs like Orforglipron (OFG) represent a promising alternative, yet their comprehensive dose-response effects on weight and glycemic parameters across different populations and follow-up durations remain underexplored. This network meta-analysis aims to clarify these effects.